193 related articles for article (PubMed ID: 23526263)
1. Vemurafenib reverses immunosuppression by myeloid derived suppressor cells.
Schilling B; Sucker A; Griewank K; Zhao F; Weide B; Görgens A; Giebel B; Schadendorf D; Paschen A
Int J Cancer; 2013 Oct; 133(7):1653-63. PubMed ID: 23526263
[TBL] [Abstract][Full Text] [Related]
2. Activated human hepatic stellate cells induce myeloid derived suppressor cells from peripheral blood monocytes in a CD44-dependent fashion.
Höchst B; Schildberg FA; Sauerborn P; Gäbel YA; Gevensleben H; Goltz D; Heukamp LC; Türler A; Ballmaier M; Gieseke F; Müller I; Kalff J; Kurts C; Knolle PA; Diehl L
J Hepatol; 2013 Sep; 59(3):528-35. PubMed ID: 23665041
[TBL] [Abstract][Full Text] [Related]
3. A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells.
Hoechst B; Ormandy LA; Ballmaier M; Lehner F; Krüger C; Manns MP; Greten TF; Korangy F
Gastroenterology; 2008 Jul; 135(1):234-43. PubMed ID: 18485901
[TBL] [Abstract][Full Text] [Related]
4. Melanoma-educated CD14+ cells acquire a myeloid-derived suppressor cell phenotype through COX-2-dependent mechanisms.
Mao Y; Poschke I; Wennerberg E; Pico de Coaña Y; Egyhazi Brage S; Schultz I; Hansson J; Masucci G; Lundqvist A; Kiessling R
Cancer Res; 2013 Jul; 73(13):3877-87. PubMed ID: 23633486
[TBL] [Abstract][Full Text] [Related]
5. Myeloid-derived suppressor cells are associated with disease progression and decreased overall survival in advanced-stage melanoma patients.
Jordan KR; Amaria RN; Ramirez O; Callihan EB; Gao D; Borakove M; Manthey E; Borges VF; McCarter MD
Cancer Immunol Immunother; 2013 Nov; 62(11):1711-22. PubMed ID: 24072401
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of tumor-derived prostaglandin-e2 blocks the induction of myeloid-derived suppressor cells and recovers natural killer cell activity.
Mao Y; Sarhan D; Steven A; Seliger B; Kiessling R; Lundqvist A
Clin Cancer Res; 2014 Aug; 20(15):4096-106. PubMed ID: 24907113
[TBL] [Abstract][Full Text] [Related]
7. Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14⁻/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer.
Liu CY; Wang YM; Wang CL; Feng PH; Ko HW; Liu YH; Wu YC; Chu Y; Chung FT; Kuo CH; Lee KY; Lin SM; Lin HC; Wang CH; Yu CT; Kuo HP
J Cancer Res Clin Oncol; 2010 Jan; 136(1):35-45. PubMed ID: 19572148
[TBL] [Abstract][Full Text] [Related]
8. CD33
Sun Y; Shao J; Jiang F; Wang Y; Yan Q; Yu N; Zhang J; Zhang J; Li M; He Y
Am J Reprod Immunol; 2019 Jan; 81(1):e13067. PubMed ID: 30375700
[TBL] [Abstract][Full Text] [Related]
9. Vasoactive intestinal peptide induces CD14+HLA-DR‑/low myeloid-derived suppressor cells in gastric cancer.
Li G; Wu K; Tao K; Lu X; Ma J; Mao Z; Li H; Shi L; Li J; Niu Y; Xiang F; Wang G
Mol Med Rep; 2015 Jul; 12(1):760-8. PubMed ID: 25695487
[TBL] [Abstract][Full Text] [Related]
10. Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign.
Poschke I; Mougiakakos D; Hansson J; Masucci GV; Kiessling R
Cancer Res; 2010 Jun; 70(11):4335-45. PubMed ID: 20484028
[TBL] [Abstract][Full Text] [Related]
11. CD14
Bernsmeier C; Triantafyllou E; Brenig R; Lebosse FJ; Singanayagam A; Patel VC; Pop OT; Khamri W; Nathwani R; Tidswell R; Weston CJ; Adams DH; Thursz MR; Wendon JA; Antoniades CG
Gut; 2018 Jun; 67(6):1155-1167. PubMed ID: 28592438
[TBL] [Abstract][Full Text] [Related]
12. A circulating subpopulation of monocytic myeloid-derived suppressor cells as an independent prognostic/predictive factor in untreated non-small lung cancer patients.
Vetsika EK; Koinis F; Gioulbasani M; Aggouraki D; Koutoulaki A; Skalidaki E; Mavroudis D; Georgoulias V; Kotsakis A
J Immunol Res; 2014; 2014():659294. PubMed ID: 25436215
[TBL] [Abstract][Full Text] [Related]
13. Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cells.
Weide B; Martens A; Zelba H; Stutz C; Derhovanessian E; Di Giacomo AM; Maio M; Sucker A; Schilling B; Schadendorf D; Büttner P; Garbe C; Pawelec G
Clin Cancer Res; 2014 Mar; 20(6):1601-9. PubMed ID: 24323899
[TBL] [Abstract][Full Text] [Related]
14. Increased, but Functionally Impaired, CD14(+) HLA-DR(-/low) Myeloid-Derived Suppressor Cells in Psoriasis: A Mechanism of Dysregulated T Cells.
Soler DC; Young AB; Fiessinger L; Galimberti F; Debanne S; Groft S; McCormick TS; Cooper KD
J Invest Dermatol; 2016 Apr; 136(4):798-808. PubMed ID: 26807516
[TBL] [Abstract][Full Text] [Related]
15. CD14+ HLA-DR-/low MDSCs are elevated in the periphery of early-stage breast cancer patients and suppress autologous T cell proliferation.
Speigl L; Burow H; Bailur JK; Janssen N; Walter CB; Pawelec G; Shipp C
Breast Cancer Res Treat; 2018 Apr; 168(2):401-411. PubMed ID: 29230664
[TBL] [Abstract][Full Text] [Related]
16. Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma.
Zhang B; Wang Z; Wu L; Zhang M; Li W; Ding J; Zhu J; Wei H; Zhao K
PLoS One; 2013; 8(2):e57114. PubMed ID: 23437326
[TBL] [Abstract][Full Text] [Related]
17. Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3.
Trovato R; Fiore A; Sartori S; Canè S; Giugno R; Cascione L; Paiella S; Salvia R; De Sanctis F; Poffe O; Anselmi C; Hofer F; Sartoris S; Piro G; Carbone C; Corbo V; Lawlor R; Solito S; Pinton L; Mandruzzato S; Bassi C; Scarpa A; Bronte V; Ugel S
J Immunother Cancer; 2019 Sep; 7(1):255. PubMed ID: 31533831
[TBL] [Abstract][Full Text] [Related]
18. CD14(+)S100A9(+) monocytic myeloid-derived suppressor cells and their clinical relevance in non-small cell lung cancer.
Feng PH; Lee KY; Chang YL; Chan YF; Kuo LW; Lin TY; Chung FT; Kuo CS; Yu CT; Lin SM; Wang CH; Chou CL; Huang CD; Kuo HP
Am J Respir Crit Care Med; 2012 Nov; 186(10):1025-36. PubMed ID: 22955317
[TBL] [Abstract][Full Text] [Related]
19. Immunosuppressive CD14+HLA-DRlow/neg IDO+ myeloid cells in patients following allogeneic hematopoietic stem cell transplantation.
Mougiakakos D; Jitschin R; von Bahr L; Poschke I; Gary R; Sundberg B; Gerbitz A; Ljungman P; Le Blanc K
Leukemia; 2013 Feb; 27(2):377-88. PubMed ID: 22828446
[TBL] [Abstract][Full Text] [Related]
20. Expansion of myeloid-derived suppressor cells in patients with acute coronary syndrome.
Wang YG; Xiong X; Chen ZY; Liu KL; Yang JH; Wen Q; Wu FQ; Hu XF; Peng YD; Wu JJ; Lian YT; Zhang WC; Cheng LX
Cell Physiol Biochem; 2015; 35(1):292-304. PubMed ID: 25591771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
